Answers are grounded in this paper and cite their sources.
Based on meta-analysis, patients with UC who achieve endoscopic and clinical remission have significantly higher vedolizumab trough concentration during maintenance therapy. Vedolizumab trough concentration >20 μg/mL at week 6, and >12 μg/mL during maintenance may be associated with better outcomes, though cause-effect relationship remains unclear. Prospective studies on reactive and proactive therapeutic drug monitoring of vedolizumab (vs empiric dose escalation) are warranted.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: